Abciximab
Ketorolac may increase the anticoagulant activities of Abciximab.
Acebutolol
Ketorolac may decrease the antihypertensive activities of Acebutolol.
Aceclofenac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Aceclofenac.
Advertisement
Acemetacin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Acemetacin.
Acenocoumarol
Ketorolac may increase the anticoagulant activities of Acenocoumarol.
Acetaminophen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Acetaminophen.
Advertisement
Acetyl salicylate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Acetylsalicylic acid.
Adapalene
The risk or severity of adverse effects can be increased when Ketorolac is combined with Adapalene.
Alclometasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Alclometasone.
Advertisement
Aldosterone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.
Aliskiren
Ketorolac may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Alminoprofen.
Alprenolol
Ketorolac may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Ketorolac.
Amcinonide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Amcinonide.
Amikacin
Ketorolac may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Ketorolac may decrease the antihypertensive activities of Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Aminosalicylic Acid.
Amiodarone
Ketorolac may decrease the antihypertensive activities of Amiodarone.
Ancrod
Ketorolac may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Ketorolac is combined with Androstenedione.
Anhydrous Tacrolimus
Ketorolac may increase the nephrotoxic activities of Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Antipyrine.
Antithrombin III
Ketorolac may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Ketorolac may increase the anticoagulant activities of Antithrombin III human.
Apazone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Azapropazone.
Apixaban
Ketorolac may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Ketorolac is combined with Apremilast.
Arbekacin
Ketorolac may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Ketorolac may increase the anticoagulant activities of Ardeparin.
Argatroban
Ketorolac may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Ketorolac may increase the anticoagulant activities of Argatroban.
Asenapine
Ketorolac may decrease the antihypertensive activities of Asenapine.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ginseng.
Aspirin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Acetylsalicylic acid.
Atenolol
Ketorolac may decrease the antihypertensive activities of Atenolol.
Atracurium Besylate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Atracurium besylate.
Azelastine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Azelastine.
azficel-T
The risk or severity of adverse effects can be increased when Ketorolac is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketorolac.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketorolac.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketorolac.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Ketorolac.
Balsalazide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Balsalazide.
Bazedoxifene
Ketorolac may increase the thrombogenic activities of Bazedoxifene.
Becaplermin
Ketorolac may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketorolac.
Benzthiazide
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ketorolac.
Benzydamine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Benzydamine.
Betamethasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Betamethasone.
Betaxolol
Ketorolac may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Ketorolac.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketorolac.
Bisoprolol
Ketorolac may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Ketorolac may increase the anticoagulant activities of Bivalirudin.
Bopindolol
Ketorolac may decrease the antihypertensive activities of Bopindolol.
Bromfenac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Bromfenac.
Budesonide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Ketorolac.
Bupranolol
Ketorolac may decrease the antihypertensive activities of Bupranolol.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Ketorolac.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ketorolac.
Capsaicin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Capsaicin.
Captopril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Captopril.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketorolac.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketorolac.
Carprofen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Carprofen.
Carteolol
Ketorolac may decrease the antihypertensive activities of Carteolol.
Carvedilol
Ketorolac may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Ketorolac is combined with Celecoxib.
Celiprolol
Ketorolac may decrease the antihypertensive activities of Celiprolol.
Certoparin
Ketorolac may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Chloroquine.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketorolac.
Chlorotrianisene
Ketorolac may increase the thrombogenic activities of Chlorotrianisene.
Chlorphenesin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Chlorphenesin.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketorolac.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Choline magnesium trisalicylate.
Ciclesonide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Cilazapril.
Cinoxacin
Ketorolac may increase the neuroexcitatory activities of Cinoxacin.
Ciprofloxacin
Ketorolac may increase the neuroexcitatory activities of Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Cisplatin.
Citalopram
Citalopram may increase the antiplatelet activities of Ketorolac.
Citric Acid
Ketorolac may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Ketorolac may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Ketorolac is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Clodronic Acid.
Clonixin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Clonixin.
Colesevelam
Colesevelam can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Cortisone acetate.
Curcumin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Curcumin.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ketorolac.
Cyclosporine
Ketorolac may increase the nephrotoxic activities of Cyclosporine.
Dabigatran Etexilate
Ketorolac may increase the anticoagulant activities of Dabigatran etexilate.
Dalteparin
Ketorolac may increase the anticoagulant activities of Dalteparin.
Danaparoid
Ketorolac may increase the anticoagulant activities of Danaparoid.
Deferasirox
The risk or severity of adverse effects can be increased when Ketorolac is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Ketorolac is combined with Deflazacort.
Desipramine
Ketorolac may decrease the antihypertensive activities of Desipramine.
Desirudin
Ketorolac may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Ketorolac.
Dexamethasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ketorolac.
Dextran
Ketorolac may increase the anticoagulant activities of Dextran.
Diclofenac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Diclofenac.
Dicumarol
Ketorolac may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Ketorolac may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Ketorolac may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Ketorolac is combined with Diflunisal.
Difluprednate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Ketorolac.
Dihydrostreptomycin
Ketorolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Ketorolac.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ketorolac.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ketorolac.
Dipyrone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Metamizole.
Drospirenone
Ketorolac may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Ketorolac is combined with Droxicam.
Duloxetine
Duloxetine may increase the antiplatelet activities of Ketorolac.
Edetic Acid
Ketorolac may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Ketorolac may increase the anticoagulant activities of Edoxaban.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Icosapent.
Enalapril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Ketorolac is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Ketorolac is combined with Enalaprilat.
Enoxacin
Ketorolac may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Ketorolac may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Ketorolac may increase the anticoagulant activities of Enoxaparin.
Eplerenone
Ketorolac may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketorolac.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Ketorolac.
Equol, (-)-
Ketorolac may increase the thrombogenic activities of Equol.
Escitalopram
Escitalopram may increase the antiplatelet activities of Ketorolac.
Esmolol
Ketorolac may decrease the antihypertensive activities of Esmolol.
Estradiol
Ketorolac may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Ketorolac may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Ketorolac may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Ketorolac may increase the thrombogenic activities of Estradiol valerate.
Estriol
Ketorolac may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Ketorolac may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Ketorolac may increase the thrombogenic activities of Estrogens, esterified.
Estrone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Ketorolac is combined with Etanercept.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketorolac.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketorolac.
Ethinyl Estradiol
Ketorolac may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Ketorolac may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Etodolac.
Etofenamate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Etofenamate.
Etoricoxib
The risk or severity of adverse effects can be increased when Ketorolac is combined with Etoricoxib.
Evening primrose oil
The risk or severity of adverse effects can be increased when Ketorolac is combined with Evening primrose oil.
Felbinac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Felbinac.
Fenbufen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fenbufen.
Fenoprofen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fenoprofen.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ferulic acid.
Fish Oils
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fish oil.
Fleroxacin
Ketorolac may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Ketorolac.
Fludrocortisone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fludrocortisone.
Fluindione
Ketorolac may increase the anticoagulant activities of Fluindione.
Flumequine
Ketorolac may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Ketorolac is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluorometholone.
Fluoxetine
Fluoxetine may increase the antiplatelet activities of Ketorolac.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Flurbiprofen.
Fluticasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone propionate.
Fluvoxamine
Fluvoxamine may increase the antiplatelet activities of Ketorolac.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketorolac.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketorolac.
Fondaparinux sodium
Ketorolac may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Ketorolac is combined with Formestane.
Fosinopril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fosinopril.
Framycetin
Ketorolac may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Ketorolac.
Gatifloxacin
Ketorolac may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Ketorolac may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Ketorolac.
Gemifloxacin
Ketorolac may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Ketorolac may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Ketorolac may increase the thrombogenic activities of Genistein.
Gentamicin
Ketorolac may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ginseng.
Grepafloxacin
Ketorolac may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Ketorolac is combined with Haloperidol.
Heparin
Ketorolac may increase the anticoagulant activities of Heparin.
Hydralazine
Ketorolac may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketorolac.
Hydrocortisone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketorolac.
Ibandronate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ibuprofen.
Icatibant
The risk or severity of adverse effects can be increased when Ketorolac is combined with Icatibant.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Ketorolac.
Imidapril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Ketorolac.
Indobufen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Indobufen.
Indomethacin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Indomethacin.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Ketorolac.
Kanamycin
Ketorolac may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Ketorolac may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Kebuzone.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ketoprofen.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ginseng.
Labetalol
Ketorolac may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Ketorolac.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Ketorolac.
Leflunomide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Leflunomide.
Lepirudin
Ketorolac may increase the anticoagulant activities of Lepirudin.
Levobetaxolol
Ketorolac may decrease the antihypertensive activities of Levobetaxolol.
Levobunolol
Ketorolac may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Ketorolac may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Ketorolac may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Ketorolac.
Limonene, (+)-
The risk or severity of adverse effects can be increased when Ketorolac is combined with (4R)-limonene.
Lisinopril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Ketorolac is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Ketorolac.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Ketorolac.
Lomefloxacin
Ketorolac may increase the neuroexcitatory activities of Lomefloxacin.
Lornoxicam
The risk or severity of adverse effects can be increased when Ketorolac is combined with Lornoxicam.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Ketorolac.
Loteprednol
The risk or severity of adverse effects can be increased when Ketorolac is combined with Loteprednol.
Loxoprofen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Loxoprofen.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ketorolac.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Magnesium salicylate.
Masoprocol
The risk or severity of adverse effects can be increased when Ketorolac is combined with Masoprocol.
Meclofenamate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid.
Medronate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mefenamic acid.
Meloxicam
The risk or severity of adverse effects can be increased when Ketorolac is combined with Meloxicam.
Mepindolol
Ketorolac may decrease the antihypertensive activities of Mepindolol.
Mesalamine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mesalazine.
Mestranol
Ketorolac may increase the thrombogenic activities of Mestranol.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Ketorolac.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketorolac.
Methylprednisolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Methylprednisolone.
Metipranolol
Ketorolac may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketorolac.
Metoprolol
Ketorolac may decrease the antihypertensive activities of Metoprolol.
Milnacipran
Milnacipran may increase the antiplatelet activities of Ketorolac.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketorolac.
Mivacurium
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mivacurium.
Moexipril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Ketorolac.
Moxifloxacin
Ketorolac may increase the neuroexcitatory activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolic acid.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolate mofetil.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolic acid.
Nabumetone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Nabumetone.
Nadolol
Ketorolac may decrease the antihypertensive activities of Nadolol.
Nadroparin
Ketorolac may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Naftifine.
Nalidixic Acid
Ketorolac may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Naproxen.
Nebivolol
Ketorolac may decrease the antihypertensive activities of Nebivolol.
Nefazodone
Nefazodone may increase the antiplatelet activities of Ketorolac.
Neomycin
Ketorolac may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Nepafenac.
Netilmicin
Ketorolac may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Niflumic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Niflumic Acid.
Nimesulide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Nimesulide.
Norfloxacin
Ketorolac may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Ketorolac is combined with Evening primrose oil.
Ofloxacin
Ketorolac may increase the neuroexcitatory activities of Ofloxacin.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Ketorolac.
Olopatadine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Olopatadine.
Olsalazine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Olsalazine.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Ketorolac is combined with Omacetaxine mepesuccinate.
Oxaprozin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Oxaprozin.
Oxprenolol
Ketorolac may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Oxyphenbutazone.
Pamidronate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pamidronate.
Paramethasone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Ketorolac is combined with Parecoxib.
Paromomycin
Ketorolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
Paroxetine may increase the antiplatelet activities of Ketorolac.
Parthenolide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Parthenolide.
Pefloxacin
Ketorolac may increase the neuroexcitatory activities of Pefloxacin.
Penbutolol
Ketorolac may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Ketorolac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Ketorolac may increase the anticoagulant activities of Pentosan Polysulfate.
Pentoxifylline
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pentoxifylline.
Perindopril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Perindopril.
Phenindione
Ketorolac may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Ketorolac may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Phenylbutazone.
Pimecrolimus
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pimecrolimus.
Pindolol
Ketorolac may decrease the antihypertensive activities of Pindolol.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Ketorolac.
Pirfenidone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pirfenidone.
Piroxicam
The risk or severity of adverse effects can be increased when Ketorolac is combined with Piroxicam.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Piroxicam.
Plazomicin
Ketorolac may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Polyestradiol Phosphate
Ketorolac may increase the thrombogenic activities of Polyestradiol phosphate.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketorolac.
Pomalidomide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pomalidomide.
Potassium Citrate
Ketorolac may increase the anticoagulant activities of Potassium Citrate.
Practolol
Ketorolac may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Ketorolac.
Prasterone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pregnenolone.
Probenecid
The serum concentration of Ketorolac can be increased when it is combined with Probenecid.
Promestriene
Ketorolac may increase the thrombogenic activities of Promestriene.
Propafenone
Ketorolac may decrease the antihypertensive activities of Propafenone.
Propranolol
Ketorolac may decrease the antihypertensive activities of Propranolol.
protein C, human
Ketorolac may increase the anticoagulant activities of Protein C.
protein S, human
Ketorolac may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Ketorolac may increase the anticoagulant activities of Protocatechualdehyde.
Quinapril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Quinapril.
Quinestrol
Ketorolac may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketorolac.
Ramipril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ramipril.
Rapacuronium
The risk or severity of adverse effects can be increased when Ketorolac is combined with Rapacuronium.
Rescinnamine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Ketorolac is combined with Resveratrol.
Reviparin
Ketorolac may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Ketorolac may increase the anticoagulant activities of Reviparin.
Rimexolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Risedronate.
Rivaroxaban
Ketorolac may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Ketorolac is combined with Rofecoxib.
Rosoxacin
Ketorolac may increase the neuroexcitatory activities of Rosoxacin.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Ketorolac.
Salicylamide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylamide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylic acid.
Salsalate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Salsalate.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Ketorolac.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Ketorolac.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Ketorolac is combined with Serrapeptase.
Sertraline
Sertraline may increase the antiplatelet activities of Ketorolac.
Sisomicin
Ketorolac may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Citrate
Ketorolac may increase the anticoagulant activities of Sodium Citrate.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Ketorolac.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Ketorolac.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Ketorolac.
Sotalol
Ketorolac may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Ketorolac may increase the neuroexcitatory activities of Sparfloxacin.
Spirapril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Spirapril.
Spironolactone
Ketorolac may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Ketorolac may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Sulfasalazine
The risk or severity of adverse effects can be increased when Ketorolac is combined with Sulfasalazine.
Sulindac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Sulindac.
Suprofen
The risk or severity of adverse effects can be increased when Ketorolac is combined with Suprofen.
synthetic conjugated estrogens, A
Ketorolac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Ketorolac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Ketorolac may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Ketorolac.
Talinolol
Ketorolac may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Ketorolac.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Technetium Tc-99m medronate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Ketorolac.
Temafloxacin
Ketorolac may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tenoxicam.
Terbutaline
Ketorolac may decrease the antihypertensive activities of Terbutaline.
Terbutaline Sulfate
Ketorolac may decrease the antihypertensive activities of Terbutaline.
Teriflunomide
The risk or severity of adverse effects can be increased when Ketorolac is combined with Teriflunomide.
Tertatolol
Ketorolac may decrease the antihypertensive activities of Tertatolol.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tiaprofenic acid.
Tibolone
Ketorolac may increase the thrombogenic activities of Tibolone.
Tiludronate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tiludronic acid.
Timolol
Ketorolac may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Ketorolac may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tixocortol.
Tobramycin
Ketorolac may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tolfenamic Acid.
Tolmetin
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tolmetin.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Ketorolac.
Trandolapril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tranilast.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Ketorolac.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Ketorolac.
Triamcinolone
The risk or severity of adverse effects can be increased when Ketorolac is combined with Triamcinolone.
Triamterene
Ketorolac may decrease the antihypertensive activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Ketorolac is combined with Tribenoside.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketorolac.
Trisodium Citrate Anhydrous
Ketorolac may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Ketorolac is combined with Trolamine salicylate.
Trovafloxacin
Ketorolac may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Ketorolac may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Ketorolac.
Valdecoxib
The risk or severity of adverse effects can be increased when Ketorolac is combined with Valdecoxib.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Ketorolac.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Ketorolac.
Venlafaxine
Venlafaxine may increase the antiplatelet activities of Ketorolac.
Warfarin
Ketorolac may increase the anticoagulant activities of Warfarin.
Zileuton
The risk or severity of adverse effects can be increased when Ketorolac is combined with Zileuton.
Zofenopril
The risk or severity of adverse effects can be increased when Ketorolac is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Ketorolac is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Ketorolac is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Zomepirac.
